FreeTheAI

Geron Corporation Presents Clinical and Real-World Imetelstat Data at International Congresses

BullishLow impact
GERN$1.23 0.41%

Geron Corporation (GERN) announced that it is presenting real-world and clinical trial findings on imetelstat at hematology congresses in Europe and Asia. The presentations showcase data from United States health claims records and the Phase 3 IMerge study in adults with lower-risk myelodysplastic syndromes.

The data shows that approximately 67% of U.S. patients remained on imetelstat therapy at six months despite significant comorbid conditions. In addition, medical findings suggest that early temporary drops in blood cell counts during treatment may indicate higher therapeutic response and potential disease modification.

Investors and healthcare providers will monitor further updates as Geron Corporation evaluates imetelstat in additional blood cancers, including a Phase 3 study in myelofibrosis. Shares of Geron Corporation were up 0.41% at $1.225.

Key points

  • Geron Corporation highlighted new imetelstat data in lower-risk myelodysplastic syndromes at hematology meetings in Japan and Europe.
  • U.S. real-world claims data showed roughly 67% of patients remained on imetelstat treatment at six months.
  • Findings indicate that early, temporary cytopenias may correlate with better long-term clinical responses to imetelstat.
  • Imetelstat, marketed as RYTELO, is approved in the U.S. and European Union for certain blood cancer patients with anemia.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What is imetelstat used for?

Imetelstat, sold under the brand name RYTELO, is a telomerase inhibitor approved in the United States and European Union to treat adult patients with certain types of lower-risk myelodysplastic syndromes who have transfusion-dependent anemia.

What did Geron Corporation present at the hematology congresses?

Geron Corporation presented clinical and real-world evidence showing that patients using imetelstat maintained therapy through six months and that early temporary drops in blood cell counts correlated with better clinical outcomes.